FDA.reportPublic FDA data

NDC 0591-0454-60 - Gemfibrozil

This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.

Product NDC
0591-0454
Requested NDC
0591-0454-60
Package NDCs from labels
0591-0454-60, 0591-0454-05
Manufacturer
Watson Laboratories, Inc.
Effective date
2007-01-01
Current FDA listing
Not matched in FDA.report NDC product tables

DailyMed Labels#

Label, Manufacturer, Effective date table
LabelManufacturerEffective dateType
70011405 FPO Gemfibrozil Tablets USP Revised: July 2004 Rx onlyWatson Laboratories, Inc.2007-01-01HUMAN PRESCRIPTION DRUG LABELING

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0591-0454-05Gemfibrozil500 in 1 BOTTLETABLET5001
0591-0454-60Gemfibrozil60 in 1 BOTTLETABLET601

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0591-0454GEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]12 package rows20070111_A1DA5A84-7529-4F62-867F-808A6CAB40B8.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
GemfibrozilACTIVE INGREDIENTQ8X02027X3GEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
GemfibrozilACTIVE MOIETYQ8X02027X3GEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
calcium stearateINACTIVE INGREDIENT776XM7047LGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
colloidal silicon dioxideINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
croscarmellose sodiumINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
FD & C red #40 aluminum lakeINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
FD & C red #6 aluminum lakeINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
hydroxypropyl celluloseINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
microcrystalline celluloseINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
polyethylene glycolINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
polysorbate 80INACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
pregelatinized starchINACTIVE INGREDIENTGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1
titanium dioxideINACTIVE INGREDIENT15FIX9V2JPGEMFIBROZIL (GEMFIBROZIL) TABLET [WATSON LABORATORIES, INC.]1

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 3 · 44 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
GEMFIBROZILGEMFIBROZILREMEDYREPACK INC.42e40524-57e9-4fee-993f-be0fda14936b2026-09-03Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILREMEDYREPACK INC.4260d746-bb58-4e10-9ffe-fc414f22b5912026-07-08Warnings, Adverse reactionsExact identifier
rxcui: 310459
LopidGEMFIBROZILParke-Davis Div of Pfizer Incc48855b7-215e-453b-b3b1-a0f9dee7221f2026-05-21Warnings, Adverse reactionsExact identifier
rxcui: 310459
GEMFIBROZILGEMFIBROZILPreferred Pharmaceuticals, Inc.2f5738ac-1c9c-4f3a-8c7d-6039d768831e2026-05-04Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILCoupler LLC509e6e7c-bb54-f135-e063-6294a90a52792026-04-29Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILNorthstar RxLLC75cac02c-56e3-4dfe-b1e2-4ce166b288332026-04-10Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 310459
GEMFIBROZILGEMFIBROZILNuCare Pharmaceuticals,Inc.bfddc3bd-c2dc-449e-e053-2a95a90a8adc2026-03-05Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILNorthwind Health Company, LLCa95264ab-eb86-7699-e053-2995a90a3d1f2026-01-01Warnings, Adverse reactionsExact identifier
rxcui: 310459
GEMFIBROZILGEMFIBROZILA-S Medication Solutions1967afce-ce55-4b10-bd8c-e4e94130de872025-12-18Warnings, Adverse reactionsExact identifier
rxcui: 310459
GEMFIBROZILGEMFIBROZILA-S Medication Solutions929d6a30-ab06-4b43-9147-ab2cc613b41f2025-12-06Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILAmerican Health Packaging4e9e08da-9700-4934-a2b1-4f64c70ea8a22025-11-04Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILAvPAK3ebb5947-1fe5-9740-6a4b-1f8b577b27112025-10-29Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILPD-Rx Pharmaceuticals, Inc.5501438d-5247-4f2a-8e15-085276d017252025-09-16Warnings, Adverse reactionsExact identifier
rxcui: 310459
GEMFIBROZILGEMFIBROZILProficient Rx LPe52c9c88-8197-48b4-88cb-1b4b22ceaf162025-04-01Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILNuCare Pharmaceuticals,Inc.592811f2-e231-6a58-e053-2991aa0a69a92024-12-26Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILZydus Pharmaceuticals (USA) Inc.556945e8-4100-4538-bcba-af5b2f13a7e82024-11-08Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILChartwell RX, LLCb8bb442e-66dc-435e-830c-4ba3daa47c042024-10-28Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILA-S Medication Solutions16d0326a-a55b-448b-be24-a16182aaef5a2024-08-30Warnings, Adverse reactionsExact identifier
rxcui: 310459
GemfibrozilGEMFIBROZILA-S Medication Solutionsefecc680-f626-46bf-bc2b-3b5a72ba02672024-08-30Warnings, Adverse reactionsExact identifier
rxcui: 310459
GEMFIBROZILGEMFIBROZILBryant Ranch Prepackfe98f68c-7182-4a88-93a5-cbdbb37fb8c22024-08-26Warnings, Adverse reactionsExact identifier
rxcui: 310459

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.